Bevacizumab Treatment for Advanced Breast Cancer
نویسندگان
چکیده
منابع مشابه
Bevacizumab in neoadjuvant treatment for breast cancer.
To the Editor: The results of two studies, by von Minckwitz et al. (GeparQuinto [GBG44] trial; ClinicalTrials.gov number, NCT00567554)1 and Bear et al. (National Surgical Adjuvant Breast and Bowel Project [NSABP] B-40 trial, NCT00408408)2 (Jan. 26 issue), indicate an additional value of bevacizumab in neoadjuvant chemotherapy in patients with breast cancer. However, previous clinical studies ha...
متن کاملImmunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملBevacizumab for Metastatic Breast Cancer
Breast cancer is the most common cancer among women; it also contributes to a substantial proportion of the global cancer burden1. At diagnosis, metastatic breast cancer (mbca) accounts for 5%–10% of all breast cancers2. Molecular subtyping is essential when choosing a treatment for mbca. The most commonly used biomarkers of treatment response are the estrogen and progesterone hormone receptors...
متن کاملBevacizumab in the treatment of metastatic breast cancer.
Increased levels of vascular endothelial growth factor (VEGF) have been associated with a poor prognosis for patients with breast cancer. In addition to its prognostic role, VEGF is also a validated target in the treatment of this disease. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors, including breast cancer. Its use in combination wi...
متن کاملBevacizumab in the treatment of HER2-negative breast cancer
Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Bevacizumab is a potent humanized monoclonal antibody to VEGF, which has shown regression of breast cancer in preclinical and clinical setting, either alone or in combination ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Oncologist
سال: 2011
ISSN: 1083-7159,1549-490X
DOI: 10.1634/theoncologist.2011-0113